#At home spectra labs series

Donor-specific Antibodies Identification.The primers and probes used in this assay are specific for all known BKV strains based on similarity search algorithms. The BKV test is designed to detect all strains of BK Virus.

BK Virus (BKV) Quantitative Real-time PCR.

#At home spectra labs series

A frequent complication after transplantation, Cytomegalovirus (CMV) infection may cause a series of direct and indirect effects that lead to increased incidence of graft rejection, opportunistic infections, and decreased allograft and patient survival.1,2 Symptomatic CMV disease in immunocompromised individuals can affect almost every organ of the body, resulting in fever, pneumonia, hepatitis, encephalitis, myelitis, colitis, uveitis, retinitis, and neuropathy.

Cytomegalovirus Quantitative Real-time PCR.

The CMV T Cell Immunity Panel measures the strength of T cell responses to CMV specific antigens.

Cytomegalovirus (CMV) can affect patients with weakened immune systems and is a common risk factor in patients following solid organ transplant.

Additional charges may apply for specimen collection, logistics or expedited turnaround testing. The Coronavirus (COVID-19) SARS-CoV-2 PCR self-pay price is $100.

COVID-19 testing is available with a self-pay price for patients who do not have health insurance or for those who intentionally choose not to submit a claim to their insurance company.

We now offer active infection testing for the detection of SARS-CoV-2 in transplant donors and recipients, using polymerase chain reaction (PCR) testing with same or next day results.

TRAC™ analyzes donor-derived cell-free-DNA levels in blood to rule out rejection in patients already suspected of rejecting.

TruGraf is the only blood test approved by CMS for surveillance to rule out “silent” subclincal acute rejection in stable kidney transplant recipients and provide assurance that patients are likely to be immune quiescent.

Infectious disease and transplant-related testing assays available through include: While transplant patients are being urged to stay at home and avoid visiting clinics for routine blood draws or surveillance biopsies, regular use of minimizes the risk to the patient and reduces load at hospitals where resources are devoted to COVID-19 care.Ĭustomize Testing for Allograft Monitoring, COVID-19, and Other Infectious Diseases These immunosuppressed and immunocompromised patients are already at risk for transplant rejection due to infection or graft failure and subsequently fall into the high-risk category for COVID-19. As our healthcare networks become increasingly stressed with Coronavirus patients, transplant patients may be unable to return to the hospital for routine and specialized post-transplant testing and management.

enables the necessary blood samples to be collected at home, helping patients to avoid the added risk of a clinic visit.ĭuring the COVID-19 pandemic, this risk is particularly prevalent.

At the same time, clinicians understand that the lack of adequate surveillance poses an even greater risk to their patients’ health. Typical protocols for the management of transplant recipients have required immunocompromised patients to make regular visits to healthcare facilities, where there may be a risk of exposure to infectious agents. Immunocompromised Patients Can Avoid Unnecessary Visits to Medical Facilities